ArticleMedicine2025
Associations of dietary flavones, particularly apigenin and luteolin, with phenotypic age acceleration: A cross-sectional study using NHANES data.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Specific flavone subclasses, particularly apigenin and luteolin, exhibit potent anti-aging properties mediated by their anti-inflammatory and antioxidant activities. However, epidemiological evidence relating these bioactive compounds to phenotypic age acceleration (PhenoAgeAccel) remains limited. We analyzed data from 10,789 US adults participating in the National Health and Nutrition Examination Survey 2007-2010 and 2017-2018 cycles. PhenoAgeAccel was calculated as the residuals from regressing phenotypic age (based on inflammatory and metabolic biomarkers) on chronological age, where positive values indicated accelerated aging. Intakes of total flavones, apigenin, and luteolin were quantified using 24-h dietary recalls. Weighted multivariable logistic regression models were used to assess associations between flavone intakes and PhenageAccel, with comprehensive adjustments for potential confounders. Restricted cubic spline models were employed to evaluate non-linear relationships. Higher total flavone intake was associated with a dose-dependent decrease in PhenoAgeAccel (P-trend < .001). In fully adjusted models, each log-unit increase (equivalent to 2.7-fold higher intake) in flavone intake corresponded to a 9.6% reduction in the odds of PhenoAgeAccel (odds ratio [OR] = 0.904, 95% confidence interval: 0.859-0.953). Similar inverse associations were observed for apigenin (Q4 vs Q1: OR = 0.647, P = .002) and luteolin (Q4 vs Q1: OR = 0.736, P = .011). Significant non-linear dose-response relationships were observed for all flavones (P-nonlinearity < 0.001). Subgroup analyses unveiled consistent associations across age, sex, and cardiometabolic status (all P-interaction > 0.05). In this nationally representative sample, higher dietary intakes of flavones, particularly apigenin and luteolin, were strongly associated with reduced PhenoAgeAccel. These findings suggest the potential role of flavones as modifiable dietary factors for healthy aging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.